Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2010
06/24/2010US20100158906 Use of recombinant monoclonal antibody with specific binding activity for cell surface phosphorylated glycoprotein in diagnosis and treatment of immune, cell proliferative and inflammatory disorders
06/24/2010US20100158879 Expression cassette and vector for transient or stable expression of exogenous molecules
06/24/2010US20100158878 Target populations of oligodendrocyte precursor cells and methods of making and using same
06/24/2010DE102008064214A1 Lokalanästhetikum zur Linderung von Brustschmerz Local anesthetic to relieve chest pain
06/23/2010EP2199299A2 Antisense modulation of survivin expression
06/23/2010EP2198887A1 Therapeutic agent for leukoderma and method for acceleration of pigmentation
06/23/2010EP2198867A1 Pyrimidine-based compounds useful as GSK-3 inhibitors
06/23/2010EP2198856A1 Process for preparing granular compositions
06/23/2010EP2197897A1 Amino acid pairing-based self assembling peptides and methods
06/23/2010EP1781276B1 Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
06/23/2010EP1670514B1 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
06/23/2010EP1511734B1 Compounds, compositions, and methods
06/23/2010EP0790835B2 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
06/23/2010CN1923285B Injectable sterile pharmaceutical formulation containing at least two active principles
06/23/2010CN1919258B Application of schisandra chinensis in the preparation of medicine for preventing and reducing toxic and side effect of antitumor agent
06/23/2010CN1809378B Methods for inhibiting viral replication in vivo
06/23/2010CN1620304B Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
06/23/2010CN1446100B Method for treating movement disorder
06/23/2010CN101754774A Synergistic combinations of VR-1 antagonists and COX-2 inhibitors
06/23/2010CN101754766A Method for pain control
06/23/2010CN101754756A Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
06/23/2010CN101745119A Polysaccharide conjugate of carboxylic acid drug, preparation method thereof and application thereof
06/23/2010CN101745113A Application of statin substance in preparation of fatty liver prevention drug
06/23/2010CN101744809A Combined drug of anethole and fenofibrate drugs
06/23/2010CN101744767A Thermal sensitive liposome preparation containing camptothecin antineoplastic agents
06/23/2010CN101744760A Sustained release carrier for difficult soluble or easy decomposable drug
06/23/2010CN101269052B Oral instant quick-effective emulsion membrane and three-dimensional printing preparation method
06/22/2010USRE41393 such as [1S-[1R*,3R*(E), 7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,13,17-trioxabicyclo[14.1.0]heptadecane-5,9-dione, used treat cancers that have demonstrated resistance to other oncolytic agents
06/22/2010USRE41390 Trace elements
06/22/2010US7741439 Isolated stra6 polypeptides
06/22/2010US7741372 Targeting p38 mitogen activated protein kinase (MAPK) cellular signaling pathway; using such as N,N'-bis(3,5-diacetylphenyl)decanediamide tetrakis(amidinohydrazone) tetrahydrochloride
06/22/2010US7741335 administering nontoxic, preferential and potent c-kit ligand inhibitors such as imatinib, to humans for treatment of inflammatory diseases such as rheumatoid arthritis
06/22/2010US7741285 APO-2 ligand/trail formulations
06/22/2010US7741282 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein
06/22/2010US7741276 Use of interleukin-18 inhibitors to inhibit tumor metastasis
06/22/2010US7741272 Inhibiting angiogenesis in a mammal by administering Eph receptor antagonist ; cardiovascular disorders
06/22/2010US7741271 atopic diseases such as allergies, asthma, eosinophilia, glomerulonephritis; hyperplastic conditions such as cancer; T cell immunologobulin and mucin domain (TIM)
06/22/2010US7741269 Exendins and exendin agonists for weight reduction and obesity
06/22/2010US7741057 Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor
06/22/2010US7741047 Using histone binding protein (RBAp48) as evaluative tool in identifying modulators for treatment of sjogren's syndrome
06/22/2010US7740854 Treatment of macrophage mediated disease
06/22/2010US7740841 Therapeutic method for reducing angiogenesis
06/22/2010US7740833 Therapeutic uses of chemokine variants
06/22/2010US7740830 Imaging, diagnosis and treatment of disease
06/22/2010US7740463 Pressurised metered dose inhalers (MDI)
06/22/2010CA2441071C Tsg101-gag interaction and use thereof
06/22/2010CA2439062C Silicon implants comprising a radionuclide for use in brachytherapy
06/22/2010CA2434067C Materials and methods relating to protein aggregation in neurodegenerative disease
06/22/2010CA2430829C Rapidly disintegrating tablet comprising an acid-labile active ingredient
06/22/2010CA2428603C Prevention of development of dyskinesias with an alfa 2-adrenoceptor antagonist
06/22/2010CA2420996C Substituted heterocyclic compounds for treating multidrug resistance
06/22/2010CA2401655C Cardioprotective phosphonates and malonates
06/22/2010CA2401593C Infusion packet with useful and decorative elements, support member, delivery system and method
06/22/2010CA2395493C Hyaluronic acid in the treatment of cancer
06/22/2010CA2384059C Method of treating cancer using tetraethyl thiuram disulfide
06/22/2010CA2353905C Chemotherapeutic composition and method
06/22/2010CA2295577C Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumors originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma
06/22/2010CA2256483C P13 lipid kinase
06/22/2010CA2216963C Tie-2 ligands, methods of making and uses thereof
06/22/2010CA2190943C Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
06/17/2010WO2010068714A2 Deuterated compounds as hepatitis c virus (hcv) inhibitors
06/17/2010WO2010067888A1 Dihydropyrimidopyrimidine derivatives
06/17/2010WO2010067869A1 Anti-viral agent and anti-viral composition
06/17/2010WO2010067755A1 Therapeutic agent for hypertension, method for treating hypertension, method for diagnosing hypertension, and method for screening therapeutic agent for hypertension
06/17/2010WO2010067671A1 Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect
06/17/2010WO2010066641A1 Oral composition
06/17/2010WO2010066593A1 Combined drug administration
06/17/2010WO2010066046A1 Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms
06/17/2010WO2010029104A3 Use of a pharmaceutical composition for the local treatment of infections, and medical product
06/17/2010WO2009140972A3 Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
06/17/2010US20100152131 Method for producing purified hematinic iron-saccharadic complex and product produced
06/17/2010US20100152130 Treatment of cancer with glutamine
06/17/2010US20100152127 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
06/17/2010US20100152095 Wound healing
06/17/2010US20100151507 Cavity Induced Allosteric Modification Of Intermolecular Interactions And Methods Of Identifying Compounds That Effect The Same
06/17/2010US20100151048 For therapy of psoriasis, eczema, ichthyosis, pruritus, dryness and dermatitis, which may cause skin to crack, chap or chafe
06/17/2010US20100151024 Therapeutic agent for ulcerative colitis
06/17/2010US20100151013 Gastric acid secretion inhibiting composition
06/17/2010US20100151006 Cancer therapy sensitizer
06/17/2010US20100150996 Athletic patch
06/17/2010US20100150947 Tolerance induction and maintenance in hematopoietic stem cell allografts
06/17/2010US20100150898 Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
06/17/2010US20100150893 Methods of organ regeneration
06/17/2010US20100150889 Polycistronic Vector For Human Induced Pluripotent Stem Cell Production
06/17/2010US20100150887 Tissue Progenitor Cells That Overexpress ERG
06/17/2010US20100150886 Method of Producing Lymphocytes
06/17/2010US20100150841 Use of Tumor Necrosis Factor-Alpha P75 Receptor for the Reduction of Inflammation
06/17/2010DE102009037359A1 Monoterpene für die Behandlung von Atemwegserkrankungen, insbesondere von bronchopulmonalen Erkrankungen Monoterpene for the treatment of respiratory disorders, in particular of bronchopulmonary disorders
06/17/2010CA2746339A1 Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms
06/17/2010CA2746258A1 Deuterated compounds as hepatitis c virus (hcv) inhibitors
06/17/2010CA2746155A1 Oral composition
06/17/2010CA2745959A1 Dihydropyrimidopyrimidine derivatives
06/17/2010CA2744367A1 Combined drug administration
06/16/2010EP2196930A1 Cavity induced allosteric modificatin of intermolecular interactions and methods of identifiying compounds that effect the same
06/16/2010EP2196533A1 Novel microorganism having gastric juice promoting action and composition secreted by the same
06/16/2010EP2196473A1 Mycobacterial antigens expressed during latency
06/16/2010EP2196226A2 Coated medical devices
06/16/2010EP2196220A1 Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient
06/16/2010EP2196218A2 Use of anti-TNFalpha antibodies and another drug
06/16/2010EP2196217A1 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
1 ... 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 ... 1151